Tim Smith

In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.

These 16-week findings have been announced by Apogee Therapeutics on APG777 in patients with moderate-to-severe atopic dermatitis.

These data point to several hidradenitis suppurativa drugs as most impactful for those with moderate-to-severe disease, based on Hidradenitis Suppurativa Clinical Response.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

This Month in Review summary includes a list of some of the most impactful news in the dermatology space from June 2025.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

This presentation, covered at SDPA, features a discussion by Ginette Okoye, MD, who highlights diagnostic challenges among even experienced clinicians.

The topics of different hair textures and the management of alopecia in patients with skin of color were highlighted by Ginette Okoye, MD, at SDPA 2025.

This session with Ginette Okoye, MD, features a discussion about hidradenitis suppurativa (HS) and several helpful approaches for patients.

Rezpegaldesleukin showed significant efficacy in improving EASI scores in moderate-to-severe atopic dermatitis patients.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.

This update by FDA officials extends the review period for ruxolitinib cream as a treatment for atopic dermatitis in children aged 2-11 years.

These data from RAD 2025 highlight upadacitinib’s efficacy in the phase 3 Measure Up 1 and 2 studies for older adults with atopic dermatitis.

Dupilumab (Dupixent) approved as the first targeted therapy for bullous pemphigoid, marking 8th indication for diseases with type 2 inflammation.

In this analysis, investigators highlight preferential options for the initial step-up of treatment among children with uncontrolled asthma on inhaled corticosteroids.

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

This June 17, 2025 SOCS News Update highlights creating strategic plans with mentors and mentees.

These data highlight the adverse events resulting from the use of dutasteride and finasteride in treating androgenetic alopecia.

These data suggest that smoking history did not impact rates of malignancy, MACE, and VTE among those with atopic dermatitis treated with upadacitinib.

This study highlights rates among females with up to 6 years of upadacitinib use of major adverse cardiovascular events, VTE, and malignancy.

These late-breaking data highlight the real-world efficacy of upadacitinib for patients with atopic dermatitis who are either bio-naïve or bio-experienced.

These late-breaking data presented at RAD 2025 highlight dupilumab’s efficacy and safety in this often neglected patient population.

These phase 3b findings highlight lebrikizumab’s efficacy and safety in adult and adolescent patients with skin of color living with atopic dermatitis.

These findings were announced by Sagimet Biosciences, showing that denifanstat met each of its primary and secondary endpoints in patients with acne.

This prospective observational study suggests that there are differences between the gut microbiome compositions of pediatric patients and others with HS.

This summary features a variety of abstracts to be presented at the RAD meeting in June 2025, highlighting new data in atopic dermatitis and the dermatology space in general.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key pulmonology updates from the 2025 American Thoracic Society (ATS) International Conference.

These data from ATS 2025 highlight patients’ real-world outcomes related to treatment of their chronic obstructive pulmonary disease (COPD) with dupilumab.